Exciting New Antibiotic Studies
Both In Lab & Humans
Antibiotics Found To Be More Effective
Part 1- In the past few years a series of studies have been done in labs that gives us an idea of what the best drugs are for treating/killing ALL forms of Lyme disease.
The work continues to built on the work of others before them, including Dr. Alan MacDonald, Eva Sapi, Ph.D., Brorson & Brorson and some additional well respected researchers.
The latest studies tested a long list of FDA approved drugs already on the market that included some currently used for treating cancer and other diseases. They also performed studies on various essential oils, spices, etc. to find out which ones, if any, might be effective in killing various forms of the Lyme bacteria.
The series of lab studies mentioned above can be found below under the heading Part 1 Studies. If you click the title you can read the abstract and/or full study linked there.
Part 2-Human Studies- Some of the antibiotics that tested successfully in the lab (Part 1 Studies) were then prescribed singly or in combination by long-time treating doctors in clinical studies of Lyme patients. Some of those studies can be found below under the heading Part 2 Human Studies. Other studies are in progress.
I share this information for several reasons, but it also comes with a warning.
Part 1 studies were performed in a lab and were not used in humans. More work needs to be done before successful protocols can be tested and established. Thankfully, we have a few researchers actually looking for a cure.
Part 2 studies were only recently performed by very experienced Lyme treating doctors using Lyme patients. More work needs to be done before all of the kinks can be worked out, but the results are looking promising.
The main reason I share this information is to let those who are suffering know that there is hope and we are finally moving towards finding a cure!
Thanks so much to the lab researchers and physicians named below on their studies. Keep up the fantastic work!
Part 1- Lab Studies
Essential Oils with High Activity against Stationary Phase Bartonella henselae
by Xiao Ma, Wanliang Shi and Ying Zhang *
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(4), 246; https://doi.org/10.3390/antibiotics8040246
Link to Study
https://www.mdpi.com/2079-6382/8/4/246
Article- These 10 essential oils can kill persistent Lyme disease
https://www.medicalnewstoday.com/articles/323881.php#1
~~
Feng J, Li T, Yee R, Yuan Y, Bai C, Cai M, Shi W, Embers M, Brayton C, Saeki H, Gabrielson K, Zhang Y.
Discov Med. 2019 Mar;27(148):125-138.
~~
Identification of Essential Oils with Strong Activity against Stationary Phase Borrelia burgdorferi.
Feng J, Shi W, Miklossy J, Tauxe GM, McMeniman CJ, Zhang Y.
Antibiotics (Basel). 2018 Oct 16;7(4). pii: E89. doi: 10.3390/antibiotics7040089.
~~
Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y.
Front Med (Lausanne). 2017 Oct 11;4:169. doi: 10.3389/fmed.2017.00169. eCollection 2017.
~~
Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro.
Feng J, Zhang S, Shi W, Zhang Y.
Antibiotics (Basel). 2017 Mar 22;6(1). pii: E10. doi: 10.3390/antibiotics6010010.
~~
Feng J, Zhang S, Shi W, Zhang Y.
Front Microbiol. 2016 Nov 4;7:1744. eCollection 2016.
~~
Feng J, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y.
Front Microbiol. 2016 May 23;7:743. doi: 10.3389/fmicb.2016.00743. eCollection 2016.
~~
Feng J, Weitner M, Shi W, Zhang S, Zhang Y.
Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062. eCollection 2016.
~~
Persister mechanisms in Borrelia burgdorferi: implications for improved intervention.
Feng J, Shi W, Zhang S, Zhang Y.
Emerg Microbes Infect. 2015 Aug;4(8):e51. doi: 10.1038/emi.2015.51. Epub 2015 Aug 19. No abstract available. Erratum in: Emerg Microbes Infect. 2015;4:e56.
~~
Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y.
Emerg Microbes Infect. 2014 Jul;3(7):e49. doi: 10.1038/emi.2014.53. Epub 2014 Jul 2.
~~
Feng J, Auwaerter PG, Zhang Y.
PLoS One. 2015 Mar 25;10(3):e0117207. doi: 10.1371/journal.pone.0117207. eCollection 2015.
~~
Feng J, Weitner M, Shi W, Zhang S, Sullivan D, Zhang Y.
Antibiotics (Basel). 2015 Sep 16;4(3):397-410. doi: 10.3390/antibiotics4030397.
~~
Feng J, Shi W, Zhang S, Zhang Y.
Emerg Microbes Infect. 2015 Jun 3;4:e31. doi: 10.1038/emi.2015.31.
~~
Feng J, Wang T, Zhang S, Shi W, Zhang Y.
PLoS One. 2014 Nov 3;9(11):e111809. doi: 10.1371/journal.pone.0111809. eCollection 2014.
~~
Economic impact of Lyme disease.
Zhang X, Meltzer MI, Peña CA, Hopkins AB, Wroth L, Fix AD.
Emerg Infect Dis. 2006 Apr;12(4):653-60.
Part 2- Human Studies
Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases
Kenneth B. Liegner
Published: 30 May 2019
QUOTE- "Abstract: Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram."
To read the full article click on this link or the pdf below.
https://drive.google.com/file/d/1ap3dgxLUoHfDhcUZPep326CDE2dLHjJI/view
More Human Studies
Horowitz RI, Freeman PR.
Int J Gen Med. 2019 Feb 18;12:101-119. doi: 10.2147/IJGM.S193608. eCollection 2019.
~~
Horowitz RI, Freeman PR.
Healthcare (Basel). 2018 Nov 5;6(4). pii: E129. doi: 10.3390/healthcare6040129.